Entity

Time filter

Source Type

Compton Martin, United Kingdom

Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: KBBE.2013.3.3-01 | Award Amount: 6.22M | Year: 2013

IB2Market aims to bring industrial biotechnology from the research lab to the market and to solve the bottle-necks in industrialisation. Specifically, the project targets the development and scale-up of new industrial biotechnology processes that have recently been developed to produce the following compounds: 1. Biosurfactants, tensioactive ingredients with a wide range of applications. Specifically, the project targets bola-sophorolipids, a completely new type of biosurfactants. 2. Specialty carbohydrates, mainly for pharmaceutical and cosmetic applications. Specifically, the project targets L-fucose and fucosylated oligosaccharides that are very difficult to produce through extraction or chemical synthesis. For both product lines, the fermentation process and down-stream processing will be optimised and scaled up to 15.000 litre scale. Sufficient amounts of product will be produced for application testing and exploratory marketing, in order to identify the most interesting market segments. The technical, economic and environmental sustainability of the process from biomass to product application will also be assessed, with particular emphasis on identifying and solving the bottlenecks in the innovation chain. A valorisation plan will be drafted to complete the innovation chain. The project will result in the industrialisation and commercialisation of the developed products and processes. The project consortium has all the required players to move a process from lab scale to industrialisation: an open innovation pilot plant (Bio Base Europe Pilot Plant), a biotech start-up company (Inbiose), marketing companies for surfactants (EOC-surfactants) and specialty carbohydrates (Carbosynth), the RTD organisation that developed the processes at lab-scale (Ghent University), an application developer (Innovhub) and service-providing SMEs (Nova institute and BCNP consultants).


Grant
Agency: Cordis | Branch: H2020 | Program: BBI-RIA | Phase: BBI.VC3.R6 | Award Amount: 5.96M | Year: 2015

This project aims to develop new processes and solve bottlenecks in the fermentative production of biosurfactants and specialty carbohydrates. Specifically, the project targets the development of innovative fermentation processes to produce the following compounds: 1. Glycolipid biosurfactants. The project targets four distinct classes of biosurfactants, specifically rhamnolipids, sophorolipids, xylolipids and mannosylerythritol-lipids with a wide range of application fields. 2. Specialty carbohydrates. Specifically, the project targets sialylated oligosaccharides, a class of very complex Human Milk Oligosaccharides that find application as a neutraceutical, pharmaceutical and cosmetic ingredient. For both product lines, microbial producer strains will be developed through metabolic engineering. The fermentation process and down-stream processing will be developed and optimized in order to obtain an industrial process. Second generation technology based on lignocellulosic substrates will also be developed. Sufficient amounts of the new products will be produced for application testing, in order to evaluate their market potential in a wide range of application fields. The technical, economic, environmental and social sustainability of the process over the whole value chain from biomass to product application will also be assessed, with an emphasis on identifying and addressing the bottlenecks in the innovation chain. A valorisation plan will be drafted to complete the innovation process. The project consortium has all the required players to obtain the expected impact: RTOs to address the research challenges in this project, an open innovation pilot plant to optimize and scale up the new processes, three biotech SMEs and three large industries to ensure the exploitation of the project results. In addition, two user groups (one for each product line) consisting of end-user companies are involved in the project.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: KBBE.2010.3.3-01 | Award Amount: 3.73M | Year: 2010

This project aims to develop novel biocatalysts for the production of glycosides (NOVOSIDES). Glycosylated compounds have a wide range of applications, but very few enzymes are able to glycosylate small organic molecules cost-efficiently at the industrial scale. Therefore, glycosylation reactions catalysed by transglycosidases, glycoside phosphorylases and glycoside hydrolases will be explored in more detail. These enzymes catalyze the transfer a glycosyl group from a cheap and readily available donor substrate to a variety of acceptors. To exploit their full potential, the enzymes specificity and stability against high temperatures and the presence of organic co-solvents will be optimised by means of directed evolution. A large and diverse collection of enzymes will first be established by screening in natural environments and by the mining of public (meta)genome databases. The enzyme collection will then be screened for activity on a variety of representative acceptors from different chemical classes. This will allow the identification of the most promising enzymes for optimisation through semi-rational and random mutagenesis. The high-throughput screening of natural and variant enzymes will be performed with newly developed fluorescent probes, that allow fast and accurate measurements of carbohydrate-active enzymes in a direct and non-destructive assay. To achieve these ambitious goals, a complementary consortium of academia and industry has been formed that covers the whole range of required expertises. The economical potential of our technology will be demonstrated by the development and scale-up of selected glycosylation reactions at pilot-plant facilities. The produced glycosides will be actively marketed to potential end-users to promote the valorisation of the projects results and to initiate future collaborations on novel target compounds.

Discover hidden collaborations